Pfizer Wins $10 Billion Metsera Acquisition in Bidding War with Novo Nordisk
Pfizer Inc. has successfully secured a deal to acquire weight-loss drug startup Metsera Inc. for $10 billion, emerging victorious from a competitive bidding process against Novo Nordisk A/S.
Key Deal Terms
Metsera announced late Friday that Pfizer will pay up to $86.25 per share. This includes an initial cash payment of $65.60 per share, with potential additional payments of up to $20.65 per share tied to achieving specific milestones.
Competitive Bidding Process
Although the deal hasn’t been officially closed, the announcement positions Pfizer to win the bidding competition against Novo Nordisk, according to Bloomberg reports.
Metsera’s board determined that Pfizer’s revised offer represented “the best transaction for shareholders,” as stated in the company’s official announcement.
The final bid represents a 5-cent per share increase over Pfizer’s previous offer, following Bloomberg’s earlier report on Friday that Pfizer had increased its bid.
